Synergy potential of indole alkaloids and its derivative against drug-resistant Escherichia coli

Chemical Biology and Drug Design

Volumn 86, Issue 6, 2015, Pages 1471-1481

  Dwivedi, Gaurav Raj ^a,b   Gupta, Shikha ^a   Maurya, Anupam ^a   Tripathi, Shubhandra ^a   Sharma, Ashok ^a   Darokar, Mahendra P ^a   Srivastava, Santosh K ^a  

^a CSIR CENTRAL INSTITUTE OF MEDICINAL AND AROMATIC PLANTS   (India)

^b BABASAHEB BHIMRAO AMBEDKAR UNIVERSITY   (India)

Author keywords

antibacterial combination; indole alkaloids; MDREC; nalidixic acid; semisynthetic derivatives; tetracycline

Indexed keywords

10 DEMETHOXYRESERPILINE; 10 METHOXY TETRAHYDROALSTONINE; AJMALICINE; AJMALINE; INDOLE ALKALOID; ISORESERPILINE; NALIDIXIC ACID; RAUWOLSCINE; RESERPILINE; SERPENTINE; TETRACYCLINE; UNCLASSIFIED DRUG; YOHIMBINE; ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BINDING AFFINITY; BROTH DILUTION; COMPUTER MODEL; CONTROLLED STUDY; DERIVATIZATION; DOWN REGULATION; DRUG PENETRATION; DRUG POTENTIATION; DRUG SOLUBILITY; ESCHERICHIA COLI; INTESTINE ABSORPTION; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR DOCKING; NONHUMAN; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; ANTIBIOTIC RESISTANCE; BACTERIAL GENE; CHEMISTRY; COMPUTER SIMULATION; DRUG DESIGN; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; MICROBIAL SENSITIVITY TEST; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANTI-BACTERIAL AGENTS; COMPUTER SIMULATION; DRUG DESIGN; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; ESCHERICHIA COLI; GENES, BACTERIAL; HUMANS; INDOLE ALKALOIDS; MICROBIAL SENSITIVITY TESTS; MOLECULAR DOCKING SIMULATION; NALIDIXIC ACID; STRUCTURE-ACTIVITY RELATIONSHIP; TETRACYCLINE;

EID: 84956590602     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12613     Document Type: Article

References (42)

1. Peleg A.Y., Hooper D.C., (2010) Hospital-acquired infections due to gram-negative bacteria. N Engl J Med; 362: 1804-1813.
2. Gaynes R., Edwards J.R., (2005) Overview of nosocomial infections caused by Gram negative bacilli. Clin Infect Dis; 41: 848-854.
3. Livermore D.M., (2009) Has the era of untreatable infections arrived? J Antimicrob Chemother; 64 (S1): i29-i36.
4. Nikaido H., (2009) Multidrug resistance in bacteria. Annu Rev Biochem; 78: 119-146.
5. Piddock L.J., (2006) Multidrug-resistance efflux pumps not just for resistance. Nature Rev Microbiol; 4: 629-636.
6. Pages J.M., Amaral L., (2009) Mechanisms of drug efflux and strategies to combat them: challenging the efflux pump of Gram-negative bacteria. Biochim Biophys Acta; 1794: 826-833.
7. Khanuja S.P.S., Arya J.S., Srivastava S.K., Shasany A.K., Kumar S., Ranganathan T., Darokar M.P., Kumar S., (2006) Antibiotic pharmaceutical composition with lysergol as bio-enhancer and method of treatment. US Patent, 20070060604.
8. Khanuja S.P.S., Arya J.S., Tiruppadiripulivur R.S.K., Saikia D., Kaur H., Singh M., Gupta S.C., Shasany A.K., Darokar M.P., Srivastava S.K., Gupta M.M., Verma S.C., Pal A., (2005) Novel Nitrite Glycosides useful as a bio-enhancer of drugs and nutrients process of its isolation from Moringa oleifera. US Patent 6,858,588.
9. Gibbons S., (2005) Plants as a source of bacterial resistance modulators and anti-infective agents. Phytochem Rev; 4: 63-78.
10. Dwivedi G.R., Upadhyay H.C., Yadav D.K., Singh V., Srivastava S.K., Khan F., Darmwal N.S., Darokar M.P., (2014) 4-hydroxy-α-tetralone and its derivative as drug resistance reversal agents in multidrug resistant Escherichia coli. Chem Biol Drug Des; 83: 482-492.
11. Maurya A., Dwivedi G.R., Darokar M.P., Shrivastava S.K., (2013) Antibacterial and synergy of clavine alkaloid lysergol and its derivatives against nalidixic acid resistant Escherichia coli. Chem Biol Drug Des; 81: 484-490.
12. Hu Y., Coates A.R., (2013) Enhancement by novel anti-methicillin-resistant Staphylococcus aureus compound HT61 of the activity of neomycin, gentamicin, mupirocin and chlorhexidine: in vitro and in vivo studies. J Antimicrob Chemother; 68: 374-384.
13. Gertsch J., (2011) Botanical drugs, synergy, and network pharmacology: forth and back to intelligent mixtures. Planta Med; 77: 1086.
14. Jia J., Zhu F., Ma F., Cao F., Li Y.X., (2009) Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov; 8: 111-128.
15. Gupta S., Khanna V.K., Maurya A., Bawankule D.U., Shukla R.K., Pal A., Srivastava S.K., (2012) Bioactivity guided isolation of antipsychotic constituents from the leaves of Rauwolfia tetraphylla L. Fitoterapia; 83: 1092-1099.
16. Dutta S., Chowdhury A.R., Srivastava S.K., Ghosh I., Datta K., (2011) Evidence for Serpentine as a novel antioxidant by a redox sensitive HABP1 overexpressing cell line by inhibiting its nuclear translocation of NF-κB. Free Radical Res; 45: 1279-1288.
17. Upadhyay H.C., Dwivedi G.R., Darokar M.P., Chaturvedi V., Srivastava S.K., (2012) Bioenhancing and antimycobacterial agents from Ammannia multiflora. Planta Med; 78: 79-81.
18. Maurya A., Dwivedi G.R., Darokar M.P., Srivastava S.K., (2014) Preparative isolation of bioenhancer loganetin from sf Alstonia scholaris by fast centrifugal partition chromatography. Sep Sci Technol; 49: 773-777.
19. Upadhyay H.C., Dwivedi G.R., Roy S., Sharma A., Darokar M.P., Srivastava S.K., (2014) Phytol derivatives as drug resistance reversal agents. ChemMedChem; 9: 1860-1868.
20. Dwivedi G.R., Maurya A., Yadav D.K., Khan F., Darokar M.P., Srivastava S.K., (2014) Drug resistance reversal potential of ursolic acid derivatives against nalidixic acid- and multi drug resistant Escherichia coli. Chem Biol Drug Des. doi: 10.1111/cbdd.12491.
21. Clinical Laboratory Standards Institute (CLSI) (2012) Performance Standards for Antimicrobial Susceptibility Testing. 22nd Informational Supplement testing M100-S15. Wayne, PA: CLSI.
22. Stermitz F.R., Lorenz P., Tawara J.N., Zenewicz L.A., Lewis K., (2000) Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5∗-methoxyhydnocarpin, a multidrug pump inhibitor. Proc Natl Acad Sci; 97: 1433-1437.
23. Eliopoulos G.M., Wennersten C.B., (2002) Antimicrobial activity of quinupristin-dalfopristin combined with other antibiotics against vancomycin resistant enterococci. Antimicrob Agents Chemother; 46: 1319-1324.
24. Eliopoulus G.M., Moellering R.C.J., (1996) Antimicrobial combinations. In:, Lorian V., editor. Antibiotics in Laboratory Medicine, 4th edn. Baltimore, MD: Williams & Wilkins; p. 330-336.
25. Viveiros M., Rodrigues L., Martins M., Couto I., Spengler G., Martins A., Amaral L., (2010) Evaluation of efflux activity of bacteria by a semi-automated fluorometric system. Methods Mol Biol; 642: 159-172.
26. Suzuki Y., Ueno S., Ohnuma R., Koyama N., (2005) Cloning, sequencing and functional expression in E. coli of the gene for a P-type Na+- ATPase of the facultative anaerobic alkaliphile, Exiguobacterium auranticum. Biochim Biophys Acta; 1727: 162-168.
27. Glavinas H., Méhn D., Jani M., Oosterhuis B., Herédi-Szabõ K., (2008) Utilization of membrane vesicle preparations to study drug-ABC transporter interactions. Expert Opin Drug Metab Toxicol; 4: 721-732.
28. Reddy G.D., Kumar K.N.V.P., Duganath N., Raavi D., Amitha K., (2012) ADMET, Docking studies & binding energy calculations of some novel ACE-inhibitors for the treatment of diabetic nephropathy. Int J Drug Dev Res; 4: 268-282.
29. Dwivedi G.R., Gupta S., Roy S., Kalani K., Pal A., Thakur J.P., Saikia D., Sharma A., Darmwal N.S., Darokar M.P., Srivastava S.K., (2013) Tricyclic sesquiterpenes from Vetiveria zizanoides (L.) Nash as antimycobacterial agents. Chem Biol Drug Des; 82: 587-594.
30. (2013) Multidrug-resistant organism & Clostridium difficile infection (MDRO/CDI) module. Centers for Disease Control and Prevention (CDC); 12: 2-42.
31. Hawkey P.M., Jones A.M., (2009) The changing epidemiology of resistance. J Antimicrob Chemother; 64 (S1): i3-i10.
32. Ling L.L., Schneider T., Peoples A.J., Spoering A.L., Engels I., Conlon B.P., Mueller A., et al,. (2015) A new antibiotic kills pathogens without detectable resistance. Nature; 517: 455-459.
33. Hassani M., (2014) The crisis of resistant Gram-negative bacterial infections: is there any hope for ESKAPE? Clin Infect Dis; 1: 1005.
34. Infectious Diseases Society of America (2010) The10 9 '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis; 50: 1081-1083.
35. Spellberg B., Bartlett J.G., Gilbert D.N., (2013) The future of antibiotics and resistance. N Engl J Med; 368: 299-302.
36. Li H.Z., Nikaido H., (2004) Efflux-mediated drug resistance in bacteria. Drugs; 64: 159-204.
37. Cos P., Vlietinck A.J., Berghe D.V., Maes L., (2006) Anti- infective potential of natural products: how to develop a stronger in vitro 'proof-of-concept'. J Ethnopharmacol; 106: 290-302.
38. Viveiros M., Dupont M., Rodrigues L., Couto I., Davin-Regli A., (2007) Antibiotic stress, genetic response and altered permeability of E. coli. PLoS ONE; 2: e36.
39. Martins M., Sujata G.D., Fanning S., Kristiansen J.E., Molnar J., Pagès J.M., Schelz Z., Spengler G., Viveiros M., Amaral L., (2008) Potential role of non-antibiotics in the treatment of multidrug-resistant Gram-negative infections: mechanisms for their direct and indirect activities. Int J Antimicrob Agents; 31: 198-208.
40. Lubelski J., Konings W.N., Driessen A.J.M., (2007) Distribution and physiology of ABC-Type transporters contributing to multidrug resistance in bacteria. Microbiol Mol Biol Rev; 71: 463-476.
41. Hurdle J.G., O'Neill A.J., Chopra I., Lee R.E., (2011) Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections. Nat Rev Microbiol; 9: 62-75.
42. Higgins C.F., (2007) Multiple molecular mechanisms for multidrug resistance transporters. Nature; 446: 749-757.